Who
Brady W. Dougan
Director
Company insider
Files Form 4 as: Director and 10% owner, Humacyte.
In numbers
- Trades disclosed
- 70
- Buys
- 8
- Sells
- 31
- Bought
- $15.4M
- Sold
- $75.5M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 26 Aug 2021
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —0 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —0 at $0.00 | filing |
| 16 Nov 2025filed 17 Nov 2025 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —311,100 at $0.00 | filing |
| 20 Aug 2025filed 20 Aug 2025 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $935K591,685 at $1.58 | filing |
| 19 Aug 2025filed 20 Aug 2025 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $1.8M1,100,000 at $1.63 | filing |
| 18 Aug 2025filed 20 Aug 2025 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $1.0M549,360 at $1.83 | filing |
| 12 Jun 2025filed 16 Jun 2025 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —0 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,130,311 at $0.00 | filing |
| 19 Dec 2024filed 20 Dec 2024 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —525 at $0.00 | filing |
| 20 Nov 2024filed 20 Nov 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $1.2M261,369 at $4.40 | filing |
| 19 Nov 2024filed 21 Nov 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $7,9791,797 at $4.44 | filing |
| 19 Nov 2024filed 20 Nov 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $1.9M427,459 at $4.34 | filing |
| 18 Nov 2024filed 20 Nov 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $3.6M811,172 at $4.44 | filing |
| 10 Sep 2024filed 11 Sep 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $1.5M288,674 at $5.23 | filing |
| 9 Sep 2024filed 11 Sep 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $855K157,704 at $5.42 | filing |
| 29 Aug 2024filed 3 Sep 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $8,0041,222 at $6.55 | filing |
| 29 Aug 2024filed 29 Aug 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $2.2M352,112 at $6.35 | filing |
| 28 Aug 2024filed 29 Aug 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $1.8M277,090 at $6.47 | filing |
| 27 Aug 2024filed 29 Aug 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $1.7M252,676 at $6.71 | filing |
| 13 Jun 2024filed 17 Jun 2024 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by HospitalsHUMA · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Brady W. Dougan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.